Truist Securities Reiterates Buy Rating, $50 Price Target on Marinus Pharmaceuticals (MRNS) Following Q1 Report, "Increasingly Bullish on TSC Indication for Oral GNX"
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $50.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
